Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
disitamab vedotin + gemcitabine
- Development stage
- Unknown
- Lead developer
- RemeGen
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Disitamab vedotin (RC48-ADC) is a HER2-targeted antibody-drug conjugate composed of a humanized anti-HER2 monoclonal antibody (hertuzumab) linked to the cytotoxic agent monomethyl auristatin E (MMAE) via a cleavable linker. It selectively binds to HER2-expressing tumor cells, is internalized by endocytosis, and releases MMAE intracellularly to disrupt microtubule formation and induce apoptosis. The drug has demonstrated efficacy in HER2-positive and HER2-low cancers such as metastatic urothelial carcinoma, gastric cancer, and breast cancer[2][4][5]. Gemcitabine is a nucleoside analog used as chemotherapy that inhibits DNA synthesis. The combination of RC48-ADC with gemcitabine aims to enhance antitumor activity through complementary mechanisms—targeted delivery of cytotoxin by RC48-ADC and broad cytotoxicity from gemcitabine[1]. Disitamab vedotin was developed by RemeGen for the treatment of various solid tumors.
- Brand names
- AidexiGemzar
- Other names
- disitamab vedotin + gemcitabine
02
Targets
DNA polymerase familyERBB2 (Erb-b2 receptor tyrosine kinase 2)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on disitamab vedotin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on disitamab vedotin + gemcitabine.